Relmada Therapeutics - Latest Emails, Sales & DealsSEC Filing Alert for Relmada Therapeutics, Inc.January 6, 2025 - 13 days agoSEC Filing Alert for Relmada Therapeutics, Inc.December 9, 2024 - 1 month agoRelmada Therapeutics to discontinue the Reliance II and Relight Phase 3 studies of REL-1017December 9, 2024 - 1 month agoRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017December 9, 2024 - 1 month agoRelmada Therapeutics to Present at Jefferies London Healthcare ConferenceDecember 5, 2024 - 1 month agoRelmada Therapeutics to Present at Jefferies London Healthcare ConferenceDecember 5, 2024 - 1 month agoRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary EfficacyDecember 4, 2024 - 1 month agoSEC Filing Alert for Relmada Therapeutics, Inc.December 4, 2024 - 1 month agoRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDecember 4, 2024 - 1 month agoRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseNovember 15, 2024 - 2 months agoRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for metabolic diseaseNovember 15, 2024 - 2 months agoSEC Filing Alert for Relmada Therapeutics, Inc.November 15, 2024 - 2 months agoRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 - 2 months agoSEC Filing Alert for Relmada Therapeutics, Inc.November 8, 2024 - 2 months agoRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 - 2 months agoRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024November 5, 2024 - 2 months agoRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024November 5, 2024 - 2 months agoSEC Filing Alert for Relmada Therapeutics, Inc.October 23, 2024 - 2 months agoSEC Filing Alert for Relmada Therapeutics, Inc.September 12, 2024 - 4 months agoSEC Filing Alert for Relmada Therapeutics, Inc.September 12, 2024 - 4 months agoSEC Filing Alert for Relmada Therapeutics, Inc.September 12, 2024 - 4 months agoSEC Filing Alert for Relmada Therapeutics, Inc.September 12, 2024 - 4 months agoSEC Filing Alert for Relmada Therapeutics, Inc.August 30, 2024 - 4 months agoRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 7, 2024 - 5 months agoSEC Filing Alert for Relmada Therapeutics, Inc.August 7, 2024 - 5 months agoRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 7, 2024 - 5 months agoRelmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024August 5, 2024 - 5 months agoRelmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024August 5, 2024 - 5 months agoRelmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical PsychiatryJune 18, 2024 - 7 months agoRelmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical PsychiatryJune 18, 2024 - 7 months agoRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 10, 2024 - 7 months agoRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 10, 2024 - 7 months agoRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare ConferenceJune 3, 2024 - 7 months agoRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare ConferenceJune 3, 2024 - 7 months agoSEC Filing Alert for Relmada Therapeutics, Inc.May 30, 2024 - 7 months agoSEC Filing Alert for Relmada Therapeutics, Inc.May 30, 2024 - 7 months agoRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 - 8 months agoSEC Filing Alert for Relmada Therapeutics, Inc.May 8, 2024 - 8 months agoRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 - 8 months agoRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024May 6, 2024 - 8 months agoRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024May 6, 2024 - 8 months agoSEC Filing Alert for Relmada Therapeutics, Inc.April 9, 2024 - 9 months agoSEC Filing Alert for Relmada Therapeutics, Inc.April 9, 2024 - 9 months agoRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 - 10 months agoRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 - 10 months agoSEC Filing Alert for Relmada Therapeutics, Inc.March 19, 2024 - 10 months agoSEC Filing Alert for Relmada Therapeutics, Inc.March 19, 2024 - 10 months agoRelmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024March 12, 2024 - 10 months agoRelmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024March 12, 2024 - 10 months agoSEC Filing Alert for Relmada Therapeutics, Inc.March 6, 2024 - 10 months agoRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceMarch 5, 2024 - 10 months agoRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceMarch 5, 2024 - 10 months agoSEC Filing Alert for Relmada Therapeutics, Inc.February 20, 2024 - 11 months agoSEC Filing Alert for Relmada Therapeutics, Inc.February 14, 2024 - 11 months agoSEC Filing Alert for Relmada Therapeutics, Inc.February 14, 2024 - 11 months agoSEC Filing Alert for Relmada Therapeutics, Inc.February 13, 2024 - 11 months agoRelmada Therapeutics Provides Corporate UpdateJanuary 4, 2024 - 12 months agoRelmada Therapeutics Provides Corporate UpdateJanuary 4, 2024 - 12 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoSEC Filing Alert for Relmada Therapeutics, Inc.December 20, 2023 - 13 months agoRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 - 14 months agoSEC Filing Alert for Relmada Therapeutics, Inc.November 8, 2023 - 14 months agoSEC Filing Alert for Relmada Therapeutics, Inc.November 8, 2023 - 14 months agoRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 - 14 months agoRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023November 3, 2023 - 14 months agoRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023November 3, 2023 - 14 months agoRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023October 11, 2023 - 15 months agoRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023October 11, 2023 - 15 months agoSEC Filing Alert for Relmada Therapeutics, Inc.October 10, 2023 - 15 months agoRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressOctober 6, 2023 - 15 months agoRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) CongressOctober 6, 2023 - 15 months agoLatest SEC Filing Alert for Relmada Therapeutics, Inc. 📑October 4, 2023 - 15 months agoSEC Filing Alert for Relmada Therapeutics, Inc.September 20, 2023 - 16 months agoRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive DisorderSeptember 20, 2023 - 16 months agoRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive DisorderSeptember 20, 2023 - 16 months agoRelmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive DisorderAugust 23, 2023 - 17 months agoSEC Filing Alert for Relmada Therapeutics, Inc.August 10, 2023 - 17 months agoSEC Filing Alert for Relmada Therapeutics, Inc.August 8, 2023 - 17 months agoSEC Filing Alert for Relmada Therapeutics, Inc.August 8, 2023 - 17 months agoRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 - 17 months agoRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 - 17 months agoRelmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023August 1, 2023 - 17 months ago1LatestFind More Emails, Deals & Sales From These StoresBody Candy Body JewelryTopsy CurvyLove Amber XThe Scotts Miracle-Gro CompanyBackerKitMagnum NutraceuticalsBumpboxxH&MFossilHorizons MusicHomebuilding & RenovatingALT FragrancesCapelli SportDaily BurnOuterknownChristianbookSacramento CountyFoot Locker CanadaLinens And HutchUla Hair